Scan imaging in adults with dermatomyositis that has not responded to treatment
Tests a scan tracer, [18F]-FAPI-74, in adults with refractory dermatomyositis.
Key facts
- Who runs it
- Farshad Moradi
- Where
- Stanford, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 21 people, planned
- Started
- Dec 2024
- Expected to end
- Oct 2028
- Type of study
- Interventional
- Treatments tested
- [18F]-FAPI-74
- Record updated
- 29 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected dermatomyositis, an inflammatory muscle and skin disease, that is hard to treat. Participants get a [18F]-FAPI-74 injection followed by PET/MRI scans.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Suspected dermatomyositis. The title describes it as refractory, meaning it does not respond well to treatment.
Main reasons for not taking part
- Women who are pregnant or may be pregnant.
- People who cannot have an MRI scan.
- People who cannot lie flat for 30 min.
- Any serious medical condition that the lead doctor thinks makes taking part too risky.
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients with suspected dermatomyositis
- Patient must be > 18 years old
- Be willing and able to provide written informed consent for the trial
Who cannot take part
- Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study
- Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women
- Contraindication to MRI or inability to lie flat for 30 min
Where in United States
- Stanford UniversityStanford, United StatesNot yet recruiting
About the trial
What the trial wants to find out
This study proposes the use of a PET isotope, [18F]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.
The group in the trial
- [18F]-FAPI-74 PET/ MRITreatment being tested
Participant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.
Treatment: [18F]-FAPI-74
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of Patients With Refractory Dermatomyositis Using [18F]- Fibroblast Activation Protein Inhibitor-74 (FAPI-74) PET/MRI Imaging
- Plain-language title
- Scan imaging in adults with dermatomyositis that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 November 2024